glp-1 compounded Despite FDA ruling, GLP-1s are still giving Novo and Lilly headaches on the market What you need to know

Patients with type 2 diabetes mellitus who were included in our study were divided into two cohorts: the first cohort included patients who were being treated with a GLP-1 RA and the second cohort included patients who were not being treated with a GLP-1 RA

Mounjaro the brand name of a novel diabetes drug manufactured by Eli Lilly and Company has emerged as a potential game-changer in the field

The tirzepatide dosing schedule starts at 2.5mg weekly and escalates to a maximum of 15mg

Tirzepatide is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 2.5 mg and gradually titrated upward (5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg) based on glycemic response and tolerability

Do I have to be severely overweight to qualify for treatment

Dual- and triple-receptor agonists also offer the potential for the treatment of obesity (3941)